The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Screening for Proteinuria in US Adults: A Cost-effectiveness Analysis
Abstract
CONTEXT: Chronic kidney disease is a growing public health problem. Screening for early identification could improve health but could also lead to unnecessary harms and excess costs. OBJECTIVE: To assess the value of periodic, population-based dipstick screening for early detection of urine protein in adults with neither hypertension nor diabetes and in adults with hypertension. DESIGN, SETTING, AND POPULATION: Cost-effectiveness analysis using a Markov decision analytic model to compare a strategy of annual screening with no screening (usual care) for proteinuria at age 50 years followed by treatment with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II-receptor blocker (ARB). MAIN OUTCOME MEASURE: Cost per quality-adjusted life-year (QALY). RESULTS: For persons with neither hypertension nor diabetes, the cost-effectiveness ratio for screening vs no screening (usual care) was unfavorable (282 818 dollars per QALY; incremental cost of 616 dollars and a gain of 0.0022 QALYs per person). However, screening such persons beginning at age 60 years yielded a more favorable ratio (53 372 dollars per QALY). For persons with hypertension, the ratio was highly favorable (18 621 dollars per QALY; incremental cost of 476 dollars and a gain of 0.03 QALYs per person). Cost-effectiveness was mediated by both chronic kidney disease progression and death prevention benefits of ACE inhibitor and ARB therapy. Influential parameters that might make screening for the general population more cost-effective include a greater incidence of proteinuria, age at screening (53 372 dollars per QALY for persons beginning screening at age 60 years), or lower frequency of screening (every 10 years: 80 700 dollars per QALY at age 50 years; 6195 dollars per QALY at age 60 years; and 5486 dollars per QALY at age 70 years). CONCLUSIONS: Early detection of urine protein to slow progression of chronic kidney disease and decrease mortality is not cost-effective unless selectively directed toward high-risk groups (older persons and persons with hypertension) or conducted at an infrequent interval of 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 5×
“For persons with each clinical history, we estimated rates of progression from normal kidney function (KDOQI stage 1) toward chronic renal insufficiency (KDOQI stages 2-4) and from chronic renal insufficiency (KDOQI stages 2-4) toward ESRD (KDOQI stage 5) from data obtained from both cohort studies and clinical trials…”
BackgroundMethodInfluentialMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
(2004) · PsycEXTRA Dataset · doi:10.1037/e442802008-001 · Cited by 2,875
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis
Robin DiMatteo, M., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002) · Medical Care · doi:10.1097/00005650-200209000-00009 · Cited by 1,490
Mann, J. F. E., Gerstein, H. C., Pogue, J., Bosch, J., Yusuf, S., & for the HOPE Investigators (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00007 · Cited by 1,372
Burt, V. L., Cutler, J. A., Higgins, M., Horan, M. J., Labarthe, D., Whelton, P., Brown, C., & Roccella, E. J. (1995) · Hypertension · doi:10.1161/01.hyp.26.1.60 · Cited by 1,252
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981 · cited 1×
“For persons with each clinical history, we estimated rates of progression from normal kidney function (KDOQI stage 1) toward chronic renal insufficiency (KDOQI stages 2-4) and from chronic renal insufficiency (KDOQI stages 2-4) toward ESRD (KDOQI stage 5) from data obtained from both cohort studies and clinical trials…”
MethodAgodoa, L. Y. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 944
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910 · cited 1×
“In contrast, although there is accruing evidence that the use of ACE inhibitor therapy decreases the incidence of death and slows clinical progression of disease for persons with chronic, nondiabetic proteinuric nephropathies, there is little evidence addressing the costeffectiveness of routine screening.(9,10,17) It…”
Willingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
Renal Insufficiency and Subsequent Death Resulting from Cardiovascular Disease in the United States
Muntner, P., He, J., Hamm, L., Loria, C., & Whelton, P. K. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133745 · Cited by 829
National Ambulatory Medical Care Survey: 2001 summary.
Cherry, D. K., Burt, C. W., & Woodwell, D. A. (2003) · PubMed · Cited by 762
One Thousand Health-Related Quality-of-Life Estimates
Tengs, T. O., & Wallace, A. (2000) · Medical Care · doi:10.1097/00005650-200006000-00004 · Cited by 662
The Patient-Provider Relationship: Attachment Theory and Adherence to Treatment in Diabetes
Ciechanowski, P. S., Katon, W. J., Russo, J. E., & Walker, E. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.29 · Cited by 597
Genetics and Pathogenesis of Polycystic Kidney Disease
Igarashi, P., & Somlo, S. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000028643.17901.42 · Cited by 593
Development of WHO guidelines on generalized cost-effectiveness analysis
Murray, C. J. L., Evans, D. B., Acharya, A., & Baltussen, R. M. P. M. (2000) · Health Economics · doi:10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o · Cited by 577
Treatment of Hypertension in Adults With Diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s80 · Cited by 497
Nelson, R. G., Bennett, P. H., Beck, G. J., Tan, M., Knowler, W. C., Mitch, W. E., Hirschman, G. H., & Myers, B. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352203 · Cited by 477
The Timing of Specialist Evaluation in Chronic Kidney Disease and Mortality
Kinchen, K. S., Sadler, J., Fink, N., Brookmeyer, R., Klag, M. J., Levey, A. S., & Powe, N. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00007 · Cited by 458
Self-citationTiming of Complications in Percutaneous Renal Biopsy
Whittier, W. L., & Korbet, S. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000102472.37947.14 · Cited by 454
Gall, M.-A., Hougaard, P., Borch-Johnsen, K., & Parving, H.-H. (1997) · BMJ · doi:10.1136/bmj.314.7083.783 · Cited by 445
Trust and the Acceptance of and Adherence to Antiretroviral Therapy
Altice, F. L., Mostashari, F., & Friedland, G. H. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200109010-00008 · Cited by 410
Is Technological Change In Medicine Worth It?
Cutler, D. M., & McClellan, M. (2001) · Health Affairs · doi:10.1377/hlthaff.20.5.11 · Cited by 377
Wang, P. S., Bohn, R. L., Knight, E., Glynn, R. J., Mogun, H., & Avorn, J. (2002) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2002.00406.x · Cited by 373
Garg, A. X., Kiberd, B. A., Clark, W. F., Haynes, R. B., & Clase, C. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00356.x · Cited by 355
Patient trust in the physician: relationship to patient requests
Thom, D. H. (2002) · Family Practice · doi:10.1093/fampra/19.5.476 · Cited by 335
Drug therapy in the elderly: what doctors believe and patients actually do
Barat, I., Andreasen, F., & Damsgaard, E. M. S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01401.x · Cited by 334
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Warram, J. H., Gearin, G., Laffel, L., & Krolewski, A. S. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v76930 · Cited by 313
Vijan, S. (2000) · JAMA · doi:10.1001/jama.283.7.889 · Cited by 295
Patterns of adherence to diabetes vision care guidelines
Schoenfeld, E. R., Greene, J. M., Wu, S. Y., & Leske, M. C. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00600-x · Cited by 253
ACE Inhibitor???Induced Angioedema: Incidence, Prevention and Management
Vleeming, W., van Amsterdam, J. G. C., Stricker, B. H., & de Wildt, D. J. (1998) · Drug Safety · doi:10.2165/00002018-199818030-00003 · Cited by 243
Barriers Pediatricians Face When Using Asthma Practice Guidelines
Cabana, M. D., Ebel, B. E., Cooper-Patrick, L., Powe, N. R., Rubin, H. R., & Rand, C. S. (2000) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.154.7.685 · Cited by 240
Self-citationImpact of Multiple Risk Factor Profiles on Determining Cardiovascular Disease Risk
Yusuf, H. R., Giles, W. H., Croft, J. B., Anda, R. F., & Casper, M. L. (1998) · Preventive Medicine · doi:10.1006/pmed.1997.0268 · Cited by 227
Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate.
Nosadini, R., Velussi, M., Brocco, E., Bruseghin, M., Abaterusso, C., Saller, A., Dalla Vestra, M., Carraro, A., Bortoloso, E., Sambataro, M., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.3.476 · Cited by 202
Okosun, I. S., Liao, Y., Rotimi, C. N., Prewitt, T. E., & Cooper, R. S. (2000) · Annals of Epidemiology · doi:10.1016/s1047-2797(00)00045-4 · Cited by 193 · cited 1×
“ing) from data on rates of hypertensive medication prescription patterns as well as prevalence rates for comorbid conditions (ie, cardiovascular disease risk factors and heart failure), which could prompt therapy with an ACE inhibitor or ARB therapy (Table 1).(10,40-53) SymptomDevelopmentand IncidentalTesting.”
BackgroundMicroalbuminuria and coronary heart disease in NIDDM: an incidence study.
Mattock, M. B., Barnes, D. J., Viberti, G., Keen, H., Burt, D., Hughes, J. M., Fitzgerald, A. P., Sandhu, B., & Jackson, P. G. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1786 · Cited by 162
Golan, L., Birkmeyer, J. D., & Welch, H. G. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-9-199911020-00005 · Cited by 160
Di Iorio, D. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.10.1015 · Cited by 159
Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys
Mendelssohn, D. C., & Cole, E. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90592-8 · Cited by 133
Voyaki, S. M., Staessen, J. A., Thijs, L., Wang, J. G., Efstratopoulos, A. D., Birkenhäger, W. H., de Leeuw, P. W., Leonetti, G., Nachev, C., Rodicio, J. L., et al. (2001) · Journal of Hypertension · doi:10.1097/00004872-200103000-00020 · Cited by 120
Physician and Patient Prevention Practices in NIDDM in a Large Urban Managed-Care Organization
Martin, T. L., Selby, J. V., & Zhang, D. (1995) · Diabetes Care · doi:10.2337/diacare.18.8.1124 · Cited by 118
Misunderstanding of Asthma Controller Medications: Association with Nonadherence
Farber, H. J., Capra, A. M., Finkelstein, J. A., Lozano, P., Quesenberry, C. P., Jensvold, N. G., Chi, F. W., & Lieu, T. A. (2003) · Journal of Asthma · doi:10.1081/jas-120017203 · Cited by 117
An Intervention for Employment Maintenance Among Blue-Collar Workers With End-Stage Renal Disease
Rasgon, S. A., Schwankovsky, L., James-Rogers, A., Widrow, L., Glick, J. A., & Butts, E. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70143-9 · Cited by 113
Wyatt, R. J., Julian, B. A., Baehler, R. W., Stafford, C. C., McMorrow, R. G., Ferguson, T., Jackson, E., Woodford, S. Y., Miller, P. M., & Kritchevsky, S. B. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v95853 · Cited by 105
Adherence to American Diabetes Association Standards of Care by Rural Health Care Providers
Coon, P. J., & Zulkowski, K. M. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2224 · Cited by 103
Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation
Kiberd, B. A., & Jindal, K. K. (1995) · BMJ · doi:10.1136/bmj.311.7020.1595 · Cited by 102
Changes in Employment Status in End-Stage Renal Disease Patients during Their First Year of Dialysis
The NECOSAD Study Group, van Manen, J. G., Korevaar, J. C., Dekker, F. W., Reuselaars, M. C., Boeschoten, E. W., & Krediet, R. T. (2001) · Peritoneal Dialysis International · doi:10.1177/089686080102100610 · Cited by 92
Shaw, S. T. (1985) · JAMA · doi:10.1001/jama.1985.03350350090028 · Cited by 88
Ten-Year Incidence of Gross Proteinuria in People With Diabetes
Klein, R., Klein, R., Moss, S. E., & Cruickshanks, K. J. (1995) · Diabetes · doi:10.2337/diab.44.8.916 · Cited by 86
Rachmani, R., Levi, Z., Lidar, M., Slavachevski, I., Half-Onn, E., & Ravid, M. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00155-8 · Cited by 77 · cited 1×
“For persons with each clinical history, we estimated rates of progression from normal kidney function (KDOQI stage 1) toward chronic renal insufficiency (KDOQI stages 2-4) and from chronic renal insufficiency (KDOQI stages 2-4) toward ESRD (KDOQI stage 5) from data obtained from both cohort studies and clinical trials…”
MethodTrends in Antihypertensive Drug Therapy of Ambulatory Patients by US Office-Based Physicians
Nelson, C. R., & Knapp, D. A. (2000) · Hypertension · doi:10.1161/01.hyp.36.4.600 · Cited by 76
Employment Status and Ability to Work among Working-Age Chronic Dialysis Patients
Kutner, N. G., BROGAN, D. R., & Fielding, B. (1991) · American Journal of Nephrology · doi:10.1159/000168333 · Cited by 65
Effect of long-term therapy with ramipril in high-risk women
Lonn, E., Roccaforte, R., Yi, Q., Dagenais, G. R., Sleight, P., Bosch, J., Suhan, P. S., Micks, M., Probstfield, J. L., Bernstein, V., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02035-1 · Cited by 57
Ni, H. (2003) · American Heart Journal · doi:10.1016/s0002-8703(02)94800-3 · Cited by 54
The impact of metabolic and blood pressure control on incidence and progression of nephropathy
Torffvit, O., & Agardh, C. (2001) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00176-3 · Cited by 40
Perindopril postmarketing surveillance: a 12 month study in 47 351 hypertensive patients
Speirs, C., Wagniart, F., & Poggi, L. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00031.x · Cited by 39
Medicaid Prescriber Compliance with Joint National Committee VI Hypertension Treatment Guidelines
Clause, S. L., & Hamilton, R. A. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a451 · Cited by 23
Cited by
Chronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
Levey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
Levey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K.-U., Nahas, M. E., Jaber, B. L., Jadoul, M., Levin, A., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002343 · Cited by 1,516
Self-citationChronic kidney disease: the global challenge
El Nahas, A. M., & Bello, A. K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17789-7 · Cited by 1,195
Chapter 1: Definition and classification of CKD
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.64 · Cited by 1,110
Metadata
- Authors
- Boulware, L. E., Jaar, B. G., Tarver-Carr, M. E., Brancati, F. L., & Powe, N. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-12-17
- Volume
- 290
- Issue
- 23
- Pages
- 3101
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2130678534
- Cited by
- 381
- References
- 64
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.